{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:49:12Z","timestamp":1793396952622,"version":"4.5.0"},"reference-count":82,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["P3-0457"],"award-info":[{"award-number":["P3-0457"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>The recent advancements in the medical management of patients with chronic heart failure with reduced ejection fraction (HFrEF) is the soluble guanylate cyclase (sGC) stimulator, vericiguat. Clinical trials have demonstrated that vericiguat effectively lowers plasma levels of NT-proBNP and reduces the risk of cardiovascular death or hospitalization in HFrEF patients, making it a class IIb recommendation for patients with worsening heart failure despite receiving guideline-directed medical therapy. However, the precise pathophysiological mechanisms underlying these clinical benefits remain unexplored. This review aims to present the signalling pathways associated with maladaptive remodeling and heart failure progression that can be modulated by sGC stimulators, focusing on the antihypertrophic, antifibrotic, and anti-inflammatory effects of NO\u2013sGC\u2013cGMP signalling observed in preclinical studies. A better understanding of the mechanisms of action of sGC stimulators could optimize heart failure treatment strategies and enable tailoring of therapies to individual patient profiles.<\/jats:p>","DOI":"10.3390\/cells14171400","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T08:06:32Z","timestamp":1757318792000},"page":"1400","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Targeting the NO\u2013sGC\u2013cGMP Pathway: Mechanisms of Action of Vericiguat in Chronic Heart Failure"],"prefix":"10.3390","volume":"14","author":[{"given":"Tine","family":"Bajec","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University Medical Centre, 1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1777-8807","authenticated-orcid":false,"given":"Gregor","family":"Poglajen","sequence":"additional","affiliation":[{"name":"Advanced Heart Failure and Transplantation Center, Department of Cardiology, University Medical Centre, 1000 Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: A comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2022","journal-title":"Cardiovasc. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1161\/CIRCRESAHA.121.318172","article-title":"Epidemiology of Heart Failure","volume":"128","author":"Roger","year":"2021","journal-title":"Circ. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cardfail.2024.07.001","article-title":"HF STATS 2024: Heart Failure Epidemiology and Outcomes Statistics An Updated 2024 Report from the Heart Failure Society of America","volume":"31","author":"Bozkurt","year":"2025","journal-title":"J. Card. Fail."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2016.163","article-title":"Neurohormonal activation in heart failure with reduced ejection fraction","volume":"14","author":"Hartupee","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013Neprilysin Inhibition Versus Enalapril in Heart Failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/ejhf.656","article-title":"Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: Implications for therapy","volume":"19","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): A multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S0008-6363(99)00169-8","article-title":"Interactions between NO and reactive oxygen species: Pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure","volume":"43","author":"Kojda","year":"1999","journal-title":"Cardiovasc. Res."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Numata, G., and Takimoto, E. (2022). Cyclic GMP and PKG Signaling in Heart Failure. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.792798"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"De Feo, D., Massari, F., Campanella, C., Livrieri, A., Ciccone, M.M., Caldarola, P., De Palo, M., and Scicchitano, P. (2025). Influence of Soluble Guanylate Cyclase on Cardiac, Vascular, and Renal Structure and Function: A Physiopathological Insight. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26104550"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2174\/092986707780059715","article-title":"Cardiovascular cGMP-generating systems in physiological and pathological conditions","volume":"14","author":"Cerra","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Russo, P., Vitiello, L., Milani, F., Volterrani, M., Rosano, G.M.C., Tomino, C., and Bonassi, S. (2024). New Therapeutics for Heart Failure Worsening: Focus on Vericiguat. J. Clin. Med., 13.","DOI":"10.20944\/preprints202407.0207.v1"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","article-title":"Soluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease","volume":"123","author":"Stasch","year":"2011","journal-title":"Circulation"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.2015.15734","article-title":"Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients with Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial","volume":"314","author":"Gheorghiade","year":"2015","journal-title":"JAMA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Butler, J., Fioretti, F., McMullan, C.J., Anstrom, K.J., Barash, I., Bonaca, M.P., Borentain, M., Corda, S., Teixeira, P.P., and Ezekowitz, J.A. (2025). Vericiguat and mortality in heart failure and reduced ejection fraction: The VICTOR trial. Eur. Heart J., ehaf655.","DOI":"10.1093\/eurheartj\/ehaf655"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Kurose, H. (2021). Cardiac Fibrosis and Fibroblasts. Cells, 10.","DOI":"10.3390\/cells10071716"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.jacc.2018.02.021","article-title":"Myocardial Interstitial Fibrosis in Heart Failure: Biological and Translational Perspectives","volume":"71","author":"Schelbert","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.rmed.2016.08.022","article-title":"Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence","volume":"122","author":"Sandner","year":"2017","journal-title":"Respir. Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Geschka, S., Kretschmer, A., Sharkovska, Y., Evgenov, O.V., Lawrenz, B., Hucke, A., Hocher, B., Stasch, J.-P., and Deli, M.A. (2011). Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0021853"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/hr.2009.64","article-title":"Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart","volume":"32","author":"Masuyama","year":"2009","journal-title":"Hypertens. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1161\/CIRCHEARTFAILURE.110.960054","article-title":"Transforming growth factor-\u03b2: Governing the transition from inflammation to fibrosis in heart failure with preserved left ventricular function","volume":"4","author":"Kapur","year":"2011","journal-title":"Circ. Heart Fail."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Hata, A., and Chen, Y.G. (2016). TGF-\u03b2 Signaling from Receptors to Smads. Cold Spring Harb. Perspect. Biol., 8.","DOI":"10.1101\/cshperspect.a022061"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Saadat, S., Noureddini, M., Mahjoubin-Tehran, M., Nazemi, S., Shojaie, L., Aschner, M., Maleki, B., Abbasi-Kolli, M., Moghadam, H.R., and Alani, B. (2020). Pivotal Role of TGF-\u03b2\/Smad Signaling in Cardiac Fibrosis: Non-coding RNAs as Effectual Players. Front. Cardiovasc. Med., 7.","DOI":"10.3389\/fcvm.2020.588347"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Zhang, Y.E. (2017). Non-Smad Signaling Pathways of the TGF-\u03b2 Family. Cold Spring Harb. Perspect. Biol., 9.","DOI":"10.1101\/cshperspect.a022129"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Foglia, B., Cannito, S., Bocca, C., Parola, M., and Novo, E. (2019). ERK Pathway in Activated, Myofibroblast-Like, Hepatic Stellate Cells: A Critical Signaling Crossroad Sustaining Liver Fibrosis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20112700"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/2211-5463.12202","article-title":"Inhibition of the TGF\u03b2 signalling pathway by cGMP and cGMP-dependent kinase I in renal fibrosis","volume":"7","author":"Schinner","year":"2017","journal-title":"FEBS Open Bio"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1136\/annrheumdis-2013-204508","article-title":"Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGF\u03b2 signalling","volume":"74","author":"Beyer","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1210\/me.2011-1009","article-title":"cGMP inhibits TGF-beta signaling by sequestering Smad3 with cytosolic beta2-tubulin in pulmonary artery smooth muscle cells","volume":"25","author":"Gong","year":"2011","journal-title":"Mol. Endocrinol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"11057","DOI":"10.1073\/pnas.1821045116","article-title":"sGC stimulator praliciguat suppresses stellate cell fibrotic transformation and inhibits fibrosis and inflammation in models of NASH","volume":"116","author":"Hall","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1161\/01.RES.0000191538.76771.66","article-title":"Nitric oxide regulates transforming growth factor-beta signaling in endothelial cells","volume":"97","author":"Saura","year":"2005","journal-title":"Circ. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1161\/CIRCRESAHA.107.157677","article-title":"Atrial natriuretic peptide inhibits transforming growth factor beta-induced Smad signaling and myofibroblast transformation in mouse cardiac fibroblasts","volume":"102","author":"Li","year":"2008","journal-title":"Circ. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1161\/CIRCULATIONAHA.110.971853","article-title":"Omega-3 fatty acids prevent pressure overload-induced cardiac fibrosis through activation of cyclic GMP\/protein kinase G signaling in cardiac fibroblasts","volume":"123","author":"Chen","year":"2011","journal-title":"Circulation"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e2000810","DOI":"10.1002\/mnfr.202000810","article-title":"Chlorogenic Acid Alleviates Hyperglycemia-Induced Cardiac Fibrosis through Activation of the NO\/cGMP\/PKG Pathway in Cardiac Fibroblasts","volume":"65","author":"Qin","year":"2021","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1253\/circj.CJ-24-0659","article-title":"Soluble Guanylate Cyclase Stimulator Vericiguat Attenuates Angiotensin II-Induced Oxidative Stress and Cardiac Remodeling","volume":"89","author":"Harada","year":"2025","journal-title":"Circ. J."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Dzia\u0142o, E., Czepiel, M., Tkacz, K., Siedlar, M., Kania, G., and B\u0142yszczuk, P. (2021). WNT\/\u03b2-Catenin Signaling Promotes TGF-\u03b2-Mediated Activation of Human Cardiac Fibroblasts by Enhancing IL-11 Production. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221810072"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41392-021-00762-6","article-title":"Wnt\/\u03b2-catenin signalling: Function, biological mechanisms, and therapeutic opportunities","volume":"7","author":"Liu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"189","DOI":"10.7555\/JBR.31.20160133","article-title":"The interaction between the Wnt\/\u03b2-catenin signaling cascade and PKG activation in cancer","volume":"31","author":"Lee","year":"2017","journal-title":"J. Biomed. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"100492","DOI":"10.1016\/j.cophys.2022.100492","article-title":"Hippo-Yap signaling in cardiac and fibrotic remodeling","volume":"26","year":"2022","journal-title":"Curr. Opin. Physiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/s41392-022-01191-9","article-title":"The Hippo signalling pathway and its implications in human health and diseases","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.canlet.2016.05.010","article-title":"Phosphodiesterase 5\/protein kinase G signal governs stemness of prostate cancer stem cells through Hippo pathway","volume":"378","author":"Liu","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1157\/13087900","article-title":"Hipertrofia cardiaca: Eventos moleculares y celulares","volume":"59","author":"Apablaza","year":"2006","journal-title":"Rev. Esp. Cardiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"75","DOI":"10.12659\/MSMBR.900437","article-title":"Cardiac Hypertrophy: An Introduction to Molecular and Cellular Basis","volume":"22","author":"Samak","year":"2016","journal-title":"Med. Sci. Monit. Basic Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1111\/bph.15333","article-title":"Stimulation of soluble guanylyl cyclase (sGC) by riociguat attenuates heart failure and pathological cardiac remodelling","volume":"179","author":"Benkner","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"11363","DOI":"10.1073\/pnas.162100799","article-title":"Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes","volume":"99","author":"Fiedler","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.yjmcc.2009.11.015","article-title":"Cyclic GMP\/PKG-Dependent Inhibition of TRPC6 Channel Activity and Expression Negatively Regulates Cardiomyocyte NFAT Activation","volume":"48","author":"Koitabashi","year":"2010","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1002\/stem.2118","article-title":"Nitric Oxide-cGMP-PKG Pathway Acts on Orai1 to Inhibit the Hypertrophy of Human Embryonic Stem Cell-Derived Cardiomyocytes","volume":"33","author":"Wang","year":"2015","journal-title":"Stem Cells"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Borges, J.I., Suster, M.S., and Lymperopoulos, A. (2023). Cardiac RGS Proteins in Human Heart Failure and Atrial Fibrillation: Focus on RGS4. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076136"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nm0104-105b","article-title":"Correction: Corrigendum: Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure","volume":"10","author":"Tang","year":"2004","journal-title":"Nat. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"C200","DOI":"10.1152\/ajpcell.00103.2006","article-title":"Inhibition of Galphaq-dependent PLC-beta1 activity by PKG and PKA is mediated by phosphorylation of RGS4 and GRK2","volume":"292","author":"Huang","year":"2007","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1161\/CIRCULATIONAHA.107.732990","article-title":"Regulator of G-Protein Signaling Subtype 4 Mediates Antihypertrophic Effect of Locally Secreted Natriuretic Peptides in the Heart","volume":"117","author":"Tokudome","year":"2008","journal-title":"Circulation"},{"key":"ref_53","first-page":"24","article-title":"The mTOR signaling pathway in cardiac aging","volume":"3","author":"Dai","year":"2023","journal-title":"J. Cardiovasc. Aging"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1242\/jcs.051011","article-title":"mTOR signaling at a glance","volume":"122","author":"Laplante","year":"2009","journal-title":"J. Cell Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/s41586-019-0895-y","article-title":"PKG1-modified TSC2 regulates mTORC1 activity to counter adverse cardiac stress","volume":"566","author":"Ranek","year":"2019","journal-title":"Nature"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Reina-Couto, M., Pereira-Terra, P., Quelhas-Santos, J., Silva-Pereira, C., Albino-Teixeira, A., and Sousa, T. (2021). Inflammation in Human Heart Failure: Major Mediators and Therapeutic Targets. Front. Physiol., 12.","DOI":"10.3389\/fphys.2021.746494"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","article-title":"NF-\u03baB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: Molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"30969","DOI":"10.1074\/jbc.272.49.30969","article-title":"Inhibition of Endothelial Vascular Cell Adhesion Molecule-1 Expression by Nitric Oxide Involves the Induction and Nuclear Translocation of I\u03baB\u03b1","volume":"272","author":"Spiecker","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1161\/01.RES.0000091074.33584.F0","article-title":"Role of Phosphodiesterase 3 in NO\/cGMP-Mediated Antiinflammatory Effects in Vascular Smooth Muscle Cells","volume":"93","author":"Aizawa","year":"2003","journal-title":"Circ. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"28263","DOI":"10.1073\/pnas.2000466117","article-title":"Stimulation of soluble guanylate cyclase exerts antiinflammatory actions in the liver through a VASP\/NF-\u03baB\/NLRP3 inflammasome circuit","volume":"117","author":"Casulleras","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1016\/j.cardfail.2022.02.010","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure","volume":"28","author":"Heidenreich","year":"2022","journal-title":"J. Card. Fail."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1002\/ehf2.15032","article-title":"Clinical profile, associated events and safety of vericiguat in a real-world cohort: The VERITA study","volume":"11","author":"Ruiz","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Zhan, Y., Li, L., Zhou, J., Ma, Y., Guan, X., Wang, S., and Chang, Y. (2025). Efficacy of vericiguat in patients with chronic heart failure and reduced ejection fraction: A prospective observational study. BMC Cardiovasc. Disord., 25.","DOI":"10.1186\/s12872-025-04477-2"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"132524","DOI":"10.1016\/j.ijcard.2024.132524","article-title":"Vericiguat in heart failure with reduced ejection fraction patients on guideline-directed medical therapy: Insights from a 6-month real-world study","volume":"417","author":"Tian","year":"2024","journal-title":"Int. J. Cardiol."},{"key":"ref_67","first-page":"204","article-title":"VERICIDuAT: Real-life study of vericiguat in patients with heart failure with reduced ejection fraction","volume":"225","author":"Botero","year":"2025","journal-title":"Rev. Cl\u00edn. Esp. (Engl. Ed.)"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/ejhf.800","article-title":"Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study","volume":"19","author":"Filippatos","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1001\/jama.2020.15922","article-title":"Effect of Vericiguat vs. Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial","volume":"324","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/ejhf.2836","article-title":"Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: The VICTORIA echocardiographic substudy","volume":"25","author":"Pieske","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Poglajen, G., Frljak, S., Zorz, N., Bajec, T., Cerar, A., Zemljic, G., Okrajsek, R., Sebestjen, M., and Vrtovec, B. (2023). Abstract 15501: Effects of Vericiguat on Right Ventricular Function in Chronic Heart Failure Patients. Circulation, 148.","DOI":"10.1161\/circ.148.suppl_1.15501"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jchf.2020.08.008","article-title":"N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study","volume":"8","author":"Ezekowitz","year":"2020","journal-title":"JACC Heart Fail."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/ejhf.1787","article-title":"Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction","volume":"22","author":"Kramer","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40292-024-00664-y","article-title":"Vericiguat on C-reactive Protein Level and Prognosis in Patients with Hypertensive Heart Failure","volume":"31","author":"Cao","year":"2024","journal-title":"High Blood Press. Cardiovasc. Prev."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.cardfail.2022.12.013","article-title":"Assessment of Biomarkers of Myocardial injury, Inflammation, and Renal Function in Heart Failure With Reduced Ejection Fraction: The VICTORIA Biomarker Substudy","volume":"29","author":"Defilippi","year":"2023","journal-title":"J. Card. Fail."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"16671","DOI":"10.1073\/pnas.0405509101","article-title":"Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis","volume":"101","author":"Melichar","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/s44161-022-00175-w","article-title":"Loss of soluble guanylyl cyclase in platelets contributes to atherosclerotic plaque formation and vascular inflammation","volume":"1","author":"Mauersberger","year":"2022","journal-title":"Nat. Cardiovasc. Res."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Gambaryan, S. (2022). The Role of NO\/sGC\/cGMP\/PKG Signaling Pathway in Regulation of Platelet Function. Cells, 11.","DOI":"10.3390\/cells11223704"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Russo, I., Barale, C., Melchionda, E., Penna, C., and Pagliaro, P. (2023). Platelets and Cardioprotection: The Role of Nitric Oxide and Carbon Oxide. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076107"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.atherosclerosis.2023.03.017","article-title":"Stimulation of soluble guanylate cyclase activity with riociguat promotes angiogenesis and improves neovascularization after limb ischemia","volume":"372","author":"Dhahri","year":"2023","journal-title":"Atherosclerosis"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"177670","DOI":"10.1016\/j.ejphar.2025.177670","article-title":"The soluble guanylate cyclase (sGC) stimulator vericiguat inhibits platelet activation and thrombosis","volume":"999","author":"Zhou","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/ejhf.2468","article-title":"Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction","volume":"24","author":"Saldarriaga","year":"2022","journal-title":"Eur. J. Heart Fail."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/17\/1400\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:41:44Z","timestamp":1760035304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/17\/1400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":82,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["cells14171400"],"URL":"https:\/\/doi.org\/10.3390\/cells14171400","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,8]]}}}